What has computer-aided molecular design ever done for drug discovery?

Expert Opinion on Drug Discovery

Volumn 1, Issue 2, 2006, Pages 103-110

  Clark, David E ^a  

^a Argenta Discovery Ltd   (United Kingdom)

Author keywords

computer aided drug design; computer aided molecular design; ligand based drug design; structure based drug design; virtual screening

Indexed keywords

EID: 34250880938     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.2.103     Document Type: Review

References (34)

1. HANSCH C, FUJITA T: p-α-π analysis; method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. (1964) 86:1616-1626.
2. SNYDER JP: Computer-assisted drug design. Part I. Conditions in the 1980s. Med. Res. Rev. (1991) 11:641-662.
3. KRIEGER JH: Molecular modeling altering how chemistry is done. Chem. Eng. News (1991) 69:21-24.
4. COHEN NC, FURET P, SELE A, TINTELNOT-BLOMLEY M, BACH LH: New professionals in drug research: the molecular modelists. Drug News Perspect. (1991) 4:459-467.
5. BOYD DB: Is rational design good for anything? ACS Symp. Ser. (1999) 719:346-356.
6. KOGA H, ITOH A, MURAYAMA S, SUZUE S, IRIKURA T: Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4- oxoquinoline-3- carboxylic acids. J. Med. Chem. (1980) 23:1358-1363.
7. DUNCIA JV, CHIU AT, CARINI DJ et al.: The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J. Med. Chem. (1990) 33:1312-1329.
8. GLEN RC, MARTIN GR, HILL AP et al.: Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties. J. Med. Chem. (1995) 38:3566-3580.
9. BEUSEN DD, MARSHALL GR: Pharmacophore definition using the active analog approach. In: Pharmacophore Perception, Development, and Use in Drug Design. Guner OF (Ed), International University Line, La Jolla, USA (2000):21-45.
10. GREER J, ERICKSON JW, BALDWIN JJ, VARNEY MD: Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem. (1994) 37:1035-1054.
11. VON ITZSTEIN M, WU W-Y, KOK GB et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 363:418-423.
12. TUNG RD, LIVINGSTON DJ, RAO BG et al.: Design and synthesis of amprenavir, a novel HIV protease inhibitor. Infect. Dis. Ther. (2002) 25:101-118.
13. SEIFERT MHJ, SCHMITT F, HERZ T, KRAMMER B: ProPose: a docking engine based on a fully configurable protein-ligand interaction model. J. Mol. Model. (2004) 10:242-357.
14. SEIFERT MHJ: ProPose: steered virtual screening by simultaneous protein-ligand docking and ligand-ligand alignment. J. Chem. Inf. Model. (2005) 45:449-460.
15. LEBAN J, SAEB W, GARCIA G, BAUMGARTNER R, KRAMER B: Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement. Bioorg. Med. Chem. Lett. (2004) 14:55-58.
16. LEBAN J, KRALIK M, MIES J, BAUMGARTNER R, GASSEN M, TASLER S: Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors. Bioorg. Med. Chem. Lett. (2006) 16:267-270.
17. BAUMGARTNER R, WALLOSCHEK M, KRALIK M et al.: Dual binding mode of a novel series of DHODH inhibitors. J. Med. Chem. (2006) 49:1239-1247.
18. BECKER OM, DHANOA DS, MARANTZ Y et al.: An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J. Med. Chem. (2006) 49:3116-3135.
19. TINTELNOT-BLOMLEY M, LEWIS RA: A critical appraisal of structure-based drug design. IDrugs (2006) 9:114-118.
20. THOMSEN R, CHRISTENSEN MH: MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem. (2006) 49:3315-3321.
21. FERRERA P, PRIESTLE JP, VANGREVELINGHE E, JACOBY E: New developments and applications of docking and high-throughput docking for drug design and in silico screening. Curr. Comput.-Aided Drug Des. (2006) 2:83-91.
22. DAVIS AM, TEAGUE SJ, KLEYWEGT GJ: Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. Engl. (2003) 42:2718-2736.
23. RODINGER T, POMES R: Enhancing the accuracy, the efficiency and the scope of free energy simulations. Curr. Opin. Struct. Biol. (2005) 15:164-170.
24. TOUNGE BA, RAJAMANI R, BAXTER EW, REITZ AB, REYNOLDS CH: Linear interaction energy models for α-secretase (BACE) inhibitors: role of van der Waals, electrostatic, and continuum-solvation terms. J. Mol. Graphics Model (2006) 24:475-484.
25. SCHULZ-GASCH T, STAHL M: Scoring functions for protein-ligand interactions: a critical perspective. Drug Discov. Today Technol. (2004) 1:231-239.
26. STAHL M, GUBA W, KANSY M: Integrating molecular design resources within modern drug discovery research: the Roche experience. Drug Discov. Today (2006) 11:326-333.
27. FIRTH-CLARK S, WILLEMS HMG, WILLIAMS A, HARRIS W: Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen. J. Chem. Inf. Model. (2006) 46:642-647.
28. BORMAN S: Drugs by design. Chem. Eng. News (2005) 83(48):28-30.
29. http://www.merck.com/newsroom/pdf/merck-financial-guidance-2006.pdf Merck financial guidance for 2006 (2006).
30. http://faculty.babson.edu/gbhardwajInventing%20Losartan-History.pdf Bhardwaj G: How the antihypertensive losartan was invented (2005).
31. http://www.astrazeneca.com/sites/7/imagebank/typeArticleparam511672/ astrazeneca-2005-annual-report.pdf AstraZeneca annual report and form 20-F information (2005).
32. http://www.ch.cam.ac.uk/staff/rcg.html Professor Robert C Glens homepage at the University of Cambridge (2006).
33. http://www.merck.com/finance/annualreport/ar2005/view-report-in-pdf.html Merck annual report (2005).
34. http://www.gsk.com/investors/annual-reports.htm GSK annual report (2005).